Allotex, founded in 2014, is a pioneering entity in the Biotechnology, Health Care, Health and Wellness, and Medical Devices industries. Headquartered in the United States, the company is making significant strides with its innovative approach to refractive surgery.
The core offering from Allotex comprises natural, tissue-based solutions, specifically precision-shaped collagen implants. These implants are engineered to integrate with the eye naturally, providing a safe, additive approach to refractive surgery. They bring together advanced technology and medical practices to fit seamlessly into modern surgical workflows, delivering clinically proven outcomes.
The company recently secured a $30.00M Series B investment in July 2023, reflecting strong investor confidence. This round was led by notable investors such as KCK Capital, Panakes Partners, Supernova Invest, Junson Capital, and Exor Ventures, underscoring the potential and innovation that Allotex offers in the medical field.